BNP Paribas Financial Markets Acquires 4,430 Shares of Chemed Corporation $CHE

BNP Paribas Financial Markets raised its holdings in shares of Chemed Corporation (NYSE:CHE) by 14.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,024 shares of the company’s stock after purchasing an additional 4,430 shares during the quarter. BNP Paribas Financial Markets owned 0.25% of Chemed worth $14,985,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. Eukles Asset Management lifted its position in Chemed by 0.4% during the third quarter. Eukles Asset Management now owns 6,031 shares of the company’s stock valued at $2,700,000 after purchasing an additional 24 shares during the last quarter. Cim LLC lifted its holdings in shares of Chemed by 1.1% in the 3rd quarter. Cim LLC now owns 2,139 shares of the company’s stock worth $958,000 after acquiring an additional 24 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Chemed by 71.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 60 shares of the company’s stock worth $27,000 after acquiring an additional 25 shares during the last quarter. Merit Financial Group LLC lifted its holdings in shares of Chemed by 4.0% in the 3rd quarter. Merit Financial Group LLC now owns 940 shares of the company’s stock worth $421,000 after acquiring an additional 36 shares during the last quarter. Finally, Renasant Bank lifted its holdings in shares of Chemed by 5.0% in the 3rd quarter. Renasant Bank now owns 824 shares of the company’s stock worth $369,000 after acquiring an additional 39 shares during the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed Stock Up 1.9%

Shares of NYSE CHE opened at $440.67 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.83 and a current ratio of 0.85. The firm has a market capitalization of $5.85 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 1.66 and a beta of 0.54. The stock has a 50 day moving average price of $409.41 and a 200 day moving average price of $424.56. Chemed Corporation has a 52-week low of $365.20 and a 52-week high of $565.66.

Chemed (NYSE:CHE) last announced its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.30 by $0.35. The firm had revenue of $657.51 million during the quarter, compared to analyst estimates of $659.22 million. Chemed had a return on equity of 27.18% and a net margin of 10.23%.Chemed’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.63 earnings per share. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Sell-side analysts expect that Chemed Corporation will post 22.3 earnings per share for the current year.

Chemed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s dividend payout ratio (DPR) is 13.08%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CHE shares. Royal Bank Of Canada raised their target price on shares of Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a report on Monday, April 27th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded shares of Chemed from a “hold” rating to a “buy” rating in a report on Sunday, May 31st. Finally, Oppenheimer lowered their target price on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Chemed presently has a consensus rating of “Hold” and an average target price of $501.50.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the transaction, the chief executive officer owned 90,219 shares of the company’s stock, valued at approximately $37,993,927.47. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 3.33% of the company’s stock.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.